IDKmonitor Adalimumab TOTAL Anti-drug antibody ELISA 96 wells
Therapeutic Drug Monitoring
Adalimumab is a recombinant protein that has the potential to induce humoral immune responses and lead to anti-drug antibody formation; a major cause of loss of response.
These Anti-drug antibodies bind and neutralise the TNFα inhibitors accelerating their clearance and reduces the efficacy of the drugs. Monitoring the efficacy of TNFα inhibitors may help clinicians schedule a successful individualised treatment strategy for their patients.
Total Anti-Adalimumab Antibody ELISA
TOTAL anti-drug antibody ELISAs enable the detection of anti-drug antibodies in the presence of circulating drug, and so are often called "Drug Tolerant" assays. The benefit of drug-tolerant assays is being able to detect lower titres of Anti-drug antibodies which could become clinically significant in certain circumstances.
Total anti-drug Antibody assays offer a greater sensitivity, unmasking the drug-bound portion of anti-drug antibodies in circulation. TOTAL anti-drug antibody analysis may be advantageous when using combination therapy such as immunosuppressants due to this increased sensitivity.
IDKmonitor® Adalimumab total-Anti-drug Antibody ELISA is a quantitative assay that involves a pre-analytical step to dissociate the anti-drug antibodies of interest from the therapeutic Adalimumab. The separated therapeutic Adalimumab is replaced by a biotinylated version of the drug, forming a the new complex which can be captured and quantified on the streptavidin coated microplate.
Drug tolerant assay for Adalimumab anti-drug antibodies
Detects Total anti-Adalimumab antibodies in Serum and Plasma
Preanalytical step to dissociate therapeutic drug from target anti-drug antibody
1 calibrator, 2 controls
Capacity for 45 samples in duplicate
Automatable on ELISA automates (e.g. Dynex D2)
Supports the investigation of primary non response and loss of response to Adalimumab
Drug tolerant assay detects total anti-Adalimumab antibodies (those free- and bound to- Adalimumab)
Helps predict long term outcome of disease in patients with sub-therapeutic Adalimumab levels
Identifies patients with low-titre anti-Adalimumab antibodies (e.g. in the case of concomitant immunosuppressant)
UK publications and evidence base
Widely available via reference laboratories in UK and Ireland
Applicable to Gastroenterology, Rheumatology
+2 to +8